The CD40-CD40L system in cardiovascular disease

References

• Noelle RJ, Ledbetter JA, Aruffo A. CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. Immunol Today. 1992;13:431–3.
   PubMedGoogle Scholar
• Ludewig B, Henn V, Schröder JM, Graf D, Kroczek RA. Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4+ CD45RA+ T cells with dendritic cells. Eur J Immunol. 1996;26:3137–43.
   PubMed Web of Science ®Google Scholar
• van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67:2–17.
   PubMed Web of Science ®Google Scholar
• Kroczek RA, Graf D, Brugnoni D, Giliani S, Korthauer U, Ugazio A, . Defective expression of CD40 ligand on T cells causes X-linked immunodeficiency with hyper-IgM (HIGM1). Immunol Rev. 1994;138:39–59.
   PubMed Web of Science ®Google Scholar
• Gauchat JF, Henchoz S, Mazzei G, Aubry JP, Brunner T, Blasey H, . Induction of human IgE synthesis in B cells by mast cells and basophils. Nature. 1993;365:340–3.
   PubMed Web of Science ®Google Scholar
• Gauchat JF, Henchoz S, Fattah D, Mazzei G, Aubry JP, Jomotte T, . CD40 ligand is functionally expressed on human eosinophils. Eur J Immunol. 1995;25:863–5.
   PubMed Web of Science ®Google Scholar
• Hermann A, Rauch BH, Braun M, Schror K, Weber AA. Platelet CD40 ligand-subcellullar localization, regulation of expression, and inhibition by clopidogrel. Platelets. 2001;12: 74–82.
   PubMed Web of Science ®Google Scholar
• Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, . Molecular and biological characterization of a murine ligand for CD40. Nature. 1992;357:80–2.
   PubMed Web of Science ®Google Scholar
• Graf D, Korthauer GD, Mages HW, Senger G, Kroczek RA. Cloning of TRAP, a ligand for CD40 on human T cells. Eur J Immunol. 1992;22:3191–4.
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001;58:4–43.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen J, Xiong Y, Da Q, Xu Y, Jiang X, . Internalization of CD40 regulates its signal transduction in vascular endothelial cells. Biochem Biophys Res Commun. 2006;345:106–17.
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res. 2001;89:1092–103.
   PubMed Web of Science ®Google Scholar
• Zirlik A, Bavendiek U, Libby P, MacFarlane L, Gerdes N, Jagielska J, . TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells. Arterioscler Thromb Vasc Biol. 2007;27:1101–7.
   PubMedGoogle Scholar
• Urbich C, Mallat Z, Tedgui A, Clauss M, Zeiher AM, Dimmeler S. Upregulation of TRAF-3 by shear stress blocks CD40-mediated endothelial activation. J Clin Invest. 2001; 108:1451–8.
   PubMed Web of Science ®Google Scholar
• Arron JR, Pewzner-Jung Y, Walsh MC, Kobayashi T, Choi Y. Regulation of the subcellular localization of tumor necrosis factor receptor associated factor (TRAF)2 by TRAF1 reveals mechanisms of TRAF2 signaling. J Exp Med. 2002;196: 923–34.
   PubMed Web of Science ®Google Scholar
• Missiou A, Wolf D, Platzer I, Ernst S, Walter C, Rudolf P, . CD40L induces inflammation and adipogenesis in adipose cells—a potential link between metabolic and cardiovascular disease. Thromb Haemost. 2010;103:788–96.
   PubMedGoogle Scholar
• Donners MM, Beckers L, Lievens D, Munnix I, Heemskerk J, Janssen BJ, . The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood. 2008;111:4596–604.
   PubMed Web of Science ®Google Scholar
• Zapata JM. TNF-receptor-associated factors as targets for drug development. Expert Opin Ther Targets. 2003;7:411–25.
   PubMed Web of Science ®Google Scholar
• Lutgens E, Lievens D, Beckers L, Wijnands E, Soehnlein O, Zernecke A, . Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med. 2010;207:391–404.
   PubMed Web of Science ®Google Scholar
• Wenzel F, Baertl A, Zimmermann N, Hohlfeld T, Giers G, Oldenburg J, . Different behaviour of soluble CD40L concentrations can be reflected by variations of preanalytical conditions. Clin Hemorheol Microcirc. 2008;39:417–22.
   PubMedGoogle Scholar
• Henn V, Steinbach S, Büchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 2001;98:1047–54.
   PubMed Web of Science ®Google Scholar
• Reinboldt S, Wenzel F, Rauch BH, Hohlfeld T, Grandoch M, Fischer JW, . Preliminary evidence for a matrix metalloproteinase-2 (MMP-2)-dependent shedding of soluble CD40 ligand (sCD40L) from activated platelets. Platelets. 2009;20: 441–4.
   PubMed Web of Science ®Google Scholar
• Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res. 2003;92: 1041–8.
   PubMed Web of Science ®Google Scholar
• Matthies KM, Newman JL, Hodzic A, Wingett DG. Differential regulation of soluble and membrane CD40L proteins in T cells. Cell Immunol. 2006;241:47–58.
   PubMed Web of Science ®Google Scholar
• Hsu YM, Lucci J, Su L, Ehrenfels B, Garber E, Thomas D. Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes. J Biol Chem. 1997; 272:911–5.
   PubMed Web of Science ®Google Scholar
• Hirohata S. Human Th1 responses driven by IL-12 are associated with enhanced expression of CD40 ligand. Clin Exp Immunol. 1999;115:78–85.
   PubMed Web of Science ®Google Scholar
• Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, . CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591–4.
   PubMed Web of Science ®Google Scholar
• Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol. 1996;14:591–617.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, Freedman JE. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol. 2005;25:2428–34.
   PubMed Web of Science ®Google Scholar
• Prasad KS, Andre P, He M, Bao M, Manganello J, Phillips DR. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci U S A. 2003;100:12367–71.
   PubMed Web of Science ®Google Scholar
• Crow AR, Leytin V, Starkey AF, Rand ML, Lazarus AH. CD154 (CD40 ligand)-deficient mice exhibit prolonged bleeding time and decreased shear-induced platelet aggregates. J Thromb Haemost. 2003;1:850–2.
   PubMedGoogle Scholar
• Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, . Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia. Effects of statin therapy. Circulation. 2002;106:399–402.
   PubMed Web of Science ®Google Scholar
• Enomoto Y, Adachi S, Matsushima-Nishiwaki R, Doi T, Niwa M, Akamatsu S, . Thromboxane A(2) promotes soluble CD40 ligand release from human platelets. Atherosclerosis. 2010;209:415–21.
   PubMed Web of Science ®Google Scholar
• Lievens D, Zernecke A, Seijkens T, Soehnlein O, Beckers L, Munnix IC, . Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood. 2010;116: 4317–27.
   PubMed Web of Science ®Google Scholar
• Aukrust P, Damas JK, Solum NO. Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation? J Am Coll Cardiol. 2004;43:2326–8.
   PubMed Web of Science ®Google Scholar
• Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation. 2003;107:1123–8.
   PubMed Web of Science ®Google Scholar
• Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger III AL, Michelson AD. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol. 2004;43:2319–25.
   PubMed Web of Science ®Google Scholar
• Garlichs CD, Eskafi S, Raaz D, Schmidt A, Ludwig J, Herrmann M, . Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart. 2001;86:649–55.
   PubMed Web of Science ®Google Scholar
• Aggarwal A, Schneider DJ, Terrien EF, Sobel, BE, Dauerman HL. Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. Am J Cardiol. 2004;93:6–9.
   PubMedGoogle Scholar
• Zirlik A, Maier C, Gerdes N, MacFarlane L, Soosairajah J, Bavendiek U, . CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation. 2007;115:1571–80.
   PubMed Web of Science ®Google Scholar
• Penno G, Pucci L, Dell’Omo G, Lucchesi D, Miccoli R, Del Prato S, . Soluble CD40 ligand levels in essential hypertensive men: evidence of a possible role of insulin resistance. Am J Hypertens. 2009;22:1007–13.
   PubMed Web of Science ®Google Scholar
• Lim HS, Blann AD, Lip GYH. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus. Relationships to cardiovascular disease and risk factor intervention. Circulation. 2004;109:2524–8.
   PubMed Web of Science ®Google Scholar
• Harding SA, Sarma J, Josephs DH, Cruden NL, Din JN, Twomey PJ, . Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation. 2004;109:1926–9.
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Gerdes N, Varo N, Reynolds RS, Horton DB, Bavendiek U, . Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation. 2002;106:2888–93.
   PubMed Web of Science ®Google Scholar
• Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, . CD40L stabilizes arterial thrombi by a B3 integrindependent mechanism. Nat Med. 2002;8:247–52.
   PubMed Web of Science ®Google Scholar
• Robertson AK, Hansson GK. T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol. 2006;26: 2421–32.
   PubMed Web of Science ®Google Scholar
• Wagner AH, Guldenzoph B, Lienenluke B Hecker M. CD154/CD40-mediated expression of CD154 in endothelial cells: consequences for endothelial cell-monocyte interaction. Arterioscler Thromb Vasc Biol. 2004;24:715–20.
   PubMed Web of Science ®Google Scholar
• Smook ML, Heeringa P, Damoiseaux JG, Daemen MJ, de Winther MP, Gijbels MJ, . Leukocyte CD40L deficiency affects the CD25(+) CD4 T cell population but does not affect atherosclerosis. Atherosclerosis. 2005;183: 275–82.
   PubMedGoogle Scholar
• Hristov M, Gümbel D, Lutgens E, Zernecke A, Weber C. Soluble CD40 ligand impairs the function of peripheral blood angiogenic outgrowth cells and increases neointimal formation after arterial injury. Circulation. 2010;121: 315–24.
   PubMed Web of Science ®Google Scholar
• Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, . Soluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003;108:1049–52.
   PubMed Web of Science ®Google Scholar
• Cipollone F, Ferri C, Desideri G, Paloscia L, Materazzo G, Mascellanti M, . Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation. 2003;108: 2776–82.
   PubMedGoogle Scholar
• Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;96:396–9.
   PubMed Web of Science ®Google Scholar
• Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schonbeck U. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem. 2002;277:25032–9.
   PubMed Web of Science ®Google Scholar
• Blann AD, Tan KT, Tayebjee MH, Davagnanam I, Moss M, Lip GY. Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty. Thromb Haemost. 2005;93:578–83.
   PubMedGoogle Scholar
• Pamuk GE, Vural O, Turgut B, Demir M, Pamuk ON, Cakir N. Increased platelet activation markers in rheumatoid arthritis: are they related with subclinical atherosclerosis? Platelets. 2008;19:146–54.
   PubMed Web of Science ®Google Scholar
• Aukrust P, Muller F, Ueland T, Berget T, Aaser E, Brunsvig A, . Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999;100:614–20.
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266–8.
   PubMed Web of Science ®Google Scholar
• Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, . Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104–11.
   PubMed Web of Science ®Google Scholar
• Davi G, Tuttolomondo A, Santilli F, Basili S, Ferrante E, Di Raimondo D, . CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke. J Atheroscler Thromb. 2009;16:707–13.
   PubMed Web of Science ®Google Scholar
• Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, . Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004;110:386–91.
   PubMed Web of Science ®Google Scholar
• Verma S, Wang CH, Li SH, Lonnb E, Charbonneau F, Title LM, . The relationship between soluble CD40 ligand levels and Framingham coronary heart disease risk score in healthy volunteers. Atherosclerosis. 2005;182:361–5.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, . Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J. 2008;29:1096–102.
   PubMed Web of Science ®Google Scholar
• Blann AD, Choudhury A, Freestone B, Patel J, Lip GY. Soluble CD40 ligand and atrial fibrillation: relationship to platelet activation, and endothelial damage/dysfunction. Int J Cardiol. 2008;127:135–7.
   PubMed Web of Science ®Google Scholar
• Ferro D, Loffredo L, Polimeni L, Fimognari F, Villari P, Pignatelli P, . Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation. Arterioscler Thromb Vasc Biol. 2007;27: 2763–8.
   PubMed Web of Science ®Google Scholar
• Choudhury A, Chung I, Panja N, Patel J, Lip GYH. Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fibrillation. Relationship to soluble p-selectin, stroke risk factors, and risk factor intervention. Chest. 2008;134:574–81.
   PubMed Web of Science ®Google Scholar
• Antoniades C, Van-Assche T, Shirodaria C, Diesch J, Antonopoulos AS, Lee J, . Preoperative sCD40L levels predict risk of atrial fibrillation after off-pump coronary artery bypass graft surgery. Circulation. 2009;120: S170–S6.
   PubMed Web of Science ®Google Scholar
• Chung I, Choudhury A, Patel J, Lip GY. Soluble CD40L, platelet surface CD40L and total platelet CD40L in congestive heart failure: relationship to platelet volume, mass and granularity. J Intern Med. 2008;263:313–21.
   PubMedGoogle Scholar
• Langer F, Ingersoll SB, Amirkhosravi A, Meyer T, Siddiqui FA, Ahmad S, . The role of CD40 in CD40L- and antibody-mediated platelet activation. Thromb Haemost. 2005;93: 1137–46.
   PubMed Web of Science ®Google Scholar
• Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000; 6:114.
   Web of Science ®Google Scholar
• Mach F, Schönbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998;394:200–3.
   PubMed Web of Science ®Google Scholar
• Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE, . Requirement for CD154 in the progression of atherosclerosis. Nat Med. 1999;5:1313–6.
   PubMed Web of Science ®Google Scholar
• Schönbeck U, Sukhova G, Shimizu K, Mach F, Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A. 2000; 7458:458–63.
   Google Scholar
• Lutgens E, Cleutjens KB, Heeneman S, Koteliansky VE, Burkly LC, Daemen MJ. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci U S A. 2000;97:7464–9.
   PubMed Web of Science ®Google Scholar
• Ahn ER, Lander G, Jy W, Bidot CJ, Jimenez JJ, Horstman LL, . Differences of soluble CD40L in sera and plasma: Implications on CD40L assay as a marker of thrombotic risk. Thromb Res. 2004;114:143–8.
   PubMedGoogle Scholar
• Mason PJ, Chakrabarti S, Albers AA, Rex S, Vitseva O, Varghese S, . Plasma, serum and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol. 2005;96:1365–9.
   PubMedGoogle Scholar
• Weber M, Rabenau B, Stanisch M, Nef HM, Möllmann H, Elsässer A, . Influence of sample type on soluble CD40 ligand assessment in patients with acute coronary syndromes. Thromb Res. 2007;120:811–4.
   PubMedGoogle Scholar
• Riondino S, Martini F, La Farina F, Spila A, Guadagni F, Ferroni P. Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions. Clin Biochem. 2010;43:666–70.
   PubMed Web of Science ®Google Scholar
• Ivandic BT, Spanuth E, Haase D, Lestin HG, Katus HA. Increased plasma concentrations of soluble cd40 ligand in acute coronary syndrome depend on in vitro platelet activation. Clin Chem. 2007;53:1231–4.
   PubMed Web of Science ®Google Scholar
• Varo N, Nuzzo R, Natal C, Libby P, Schonbeck U. Influence of pre-analytical and analytical factors on soluble CD40L measurements. Clin Sci (Lond). 2006;111:341–7.
   PubMed Web of Science ®Google Scholar
• Wykrzykowska JJ, Warnholtz A, de Jaeger P, Curzen N, Oldroyd KG, Collet JP, . Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study. J Thromb Thrombolysis. 2009;28:410–7.
   PubMed Web of Science ®Google Scholar
• Olenchock BA, Wiviott SD, Murphy SA, Cannon CP, Rifai N, Braunwald E, . Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16. J Thromb Thrombolysis. 2008;26:79–84.
   PubMed Web of Science ®Google Scholar
• Novo S, Basili S, Tantillo R, Falco A, Davì V, Novo G, . Soluble CD40L and cardiovascular risk in asymptomatic low-grade carotid stenosis. Stroke. 2005;36:673–5.
   PubMed Web of Science ®Google Scholar
• Malarstig A, Lindahl B, Wallentin L, Siegbahn A. Soluble CD40L levels are regulated by the -3459 A > G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome. Arterioscler Thromb Vasc Biol. 2006;26:1667–73.
   PubMed Web of Science ®Google Scholar
• Manenti ER, Bodanese LC, Camey SA, Polanczyk CA. Prognostic value of serum biomarkers in association with TIMI risk score for acute coronary syndromes. Clin Cardiol. 2006;29:405–10.
   PubMedGoogle Scholar
• Apple FS, Pearce LA, Chung A, Ler R, Murakami MM. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem. 2007;53:874–81.
   PubMed Web of Science ®Google Scholar
• Obradovic SD, Antovic JP, Antonijevic NM, Ratkovic NG, Vojvodic DV, Subota VS, . Elevations in soluble CD40 ligand in patients with high platelet aggregability undergoing percutaneous coronary intervention. Blood Coagul Fibrinolysis. 2009;20:283–9.
   PubMed Web of Science ®Google Scholar
• Rondina MT, Lappé JM, Carlquist JF, Muhlestein JB, Kolek MJ, Horne BD, . Soluble CD40 ligand as a predictor of coronary artery disease and long-term clinical outcomes in stable patients undergoing coronary angiography. Cardiology. 2008;109:196–201.
   PubMedGoogle Scholar
• Tousoulis D, Antoniades C, Nikolopoulou A, Koniari K, Vasiliadou C, Marinou K, . Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes. Eur J Clin Invest. 2007;37:623–8.
   PubMedGoogle Scholar
• Tanne D, Haim M, Goldbourt U, Boyko V, Reshef T, Adler Y, . CD40 ligand and risk of ischemic stroke or coronary events in patients with chronic coronary heart disease. Int J Cardiol. 2006;107:322–6.
   PubMedGoogle Scholar